Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response

키워드

참고문헌 (36)

1. Lavanchy D., "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures", J Viral Hepat, 11, pp.97~107 (2004)
2. Beasley RP., "Hepatitis B virus: the major etiology of hepatocellular carcinoma", Cancer, 61, pp.1942~1956 (1988)
3. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
4. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
5. Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
6. European Association for the Study of the Liver., "EASL clinical practice guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
7. Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
8. Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
9. Gish RG, "Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B", Gastroenterology, 133, pp.1437~1444 (2007)
10. Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
11. Pol S, "First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings:from clinical trials to clinical practice", J Viral Hepat, 19, pp.377~386 (2012)
12. Cho JY, "Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease", Gut, 63, pp.1943~1950 (2014)
13. Yang SC, "Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants", J Antimicrob Chemother, 68, pp.2154~2163 (2013)
14. Korean Association for the Study of the Liver., "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
15. Miyakawa Y, "Classifying hepatitis B virus genotypes", Intervirology, 46, pp.329~338 (2003)
16. 이중민, "말디토프 질량 분석을 이용한 한국인의 B형간염 바이러스유전자형 및 임상적 의의에 대한 재평가", Clinical and Molecular Hepatology, 10(2004), pp.260~270 (2004), 대한간학회
17. Janssen HL, "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial", Lancet, 365, pp.123~129 (2005)
18. Inoue J, "Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern", J Viral Hepat, 18, pp.206~215 (2011)
19. Moskovitz DN, "Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance", J Viral Hepat, 12, pp.398~404 (2005)
20. Yuen MF, "Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine", Antivir Ther, 8, pp.531~534 (2003)
21. Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea", Journal of Korean Medical Science, 20(5), pp.816~820 (2005), 대한의학회
22. Kim H, "Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50, pp.52~57 (2007)
23. Luo J, "Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life", Int J Med Sci, 10, pp.427~433 (2013)
24. Ono A, "Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients", J Hepatol, 57, pp.508~514 (2012)
25. Yuen MF, "Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety", Am J Gastroenterol, 106, pp.1264~1271 (2011)
26. Tenney DJ, "Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present", Antimicrob Agents Chemother, 51, pp.902~911 (2007)
27. Santantonio T, "Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B", Antivir Ther, 14, pp.557~565 (2009)
28. Delaney WE 4th, "The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro", J Virol, 77, pp.11833~11841 (2003)
29. Tenney DJ, "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine", Antimicrob Agents Chemother, 48, pp.3498~3507 (2004)
30. Lai CL, "A one-year trial of lamivudine for chronic hepatitis B: Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339, pp.61~68 (1998)
31. Liaw YF., "Therapy of chronic hepatitis B: current challenges and opportunities", J Viral Hepat, 9, pp.393~399 (2002)
32. Zoutendijk R, "Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response", Hepatology, 54, pp.443~451 (2011)
33. Nguyen T, "Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia", J Hepatol, 52, pp.508~513 (2010)
34. Thompson AJ, "Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers", Hepatology, 51, pp.1933~1944 (2010)
35. Tangkijvanich P, "Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B", J Clin Virol, 46, pp.117~123 (2009)
36. Lee MH, "Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B", J Med Virol, 83, pp.1178~1186 (2011)

관련 논문AI추천